Literatur
- 1
Agnelli G, Gallus A, Goldhaber S Z, Haas S, Huisman M V, Hull R D, Kakkar A K, Misselwitz F,
Schellong S. ODIXa-DVT Study Investigators .
Treatment
of proximal deep-vein thrombosis with the oral direct factor Xa
inhibitor rivaroxaban (BAY 59 – 7939):
the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59 – 7939
in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Circulation.
2007;
116
180-187
- 2
Buller H R, Lensing A W, Prins M H, Agnelli G, Cohen A, Gallus A S, Misselwitz F,
Raskob G, Schellong S, Segers A. Einstein-DVT
Dose-Ranging Study investigators .
A dose-ranging study
evaluating once-daily oral administration of the factor Xa inhibitor
rivaroxaban in the treatment of patients with acute symptomatic
deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.
Blood.
2008;
112
2242-2247
- 3
Eriksson B I, Borris L C, Friedman R J, Haas S, Huisman M V, Kakkar A K, Bandel T J,
Beckmann H, Muehlhofer E, Misselwitz F, Geerts W. RECORD1 Study Group .
Rivaroxaban
versus enoxaparin for thromboprophylaxis after hip arthroplasty.
New Engl J Med.
2008;
358
2765-2775
- 4
Eriksson B I, Dahl O E, Buller H R, Hettiarachchi R, Rosencher N, Bravo M L, Ahnfelt L,
Piovella F, Stangier J, Kalebo P, Reilly P. BISTRO II Study Group .
A new oral
direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin
for prevention of thromboembolic events following total hip or knee
replacement: the BISTRO II randomized trial.
Thrombos
Haemost.
2005;
3
103-111
- 5
Eriksson B I, Dahl O E, Rosencher N, Kurth A A, van Dijk C N, Frostick S P, Prins M H,
Hettiarachchi R, Hantel S, Schnee J, Buller H R. RE-NOVATE Study Group .
Dabigatran etexilate versus enoxaparin for prevention of venous
thromboembolism after total hip replacement.
Lancet.
2007;
370
949-956
- 6
Ezekowitz M D, Reilly P A, Nehmiz G, Simmers T A, Nagarakanti R, Parcham-Azad K, Pedersen K E,
Lionetti D A, Stangier J, Wallentin L.
Dabigatran with or without concomitant aspirin compared with
warfarin alone in patients with nonvalvular atrial fibrillation
(PETRO Study).
Amer J Cardiol.
2007;
100
1419-1426
- 7
Hurlen M, Smith P, Arnesen H.
Effects of warfarin, aspirin and the two combined, on mortality
and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin
Reinfarction Study) design.
Scand Cardiovasc J.
2000;
34
168-171
- 8
Kakkar A K, Brenner B, Dahl O E, Eriksson B I, Mouret P, Muntz J, Soglian A G, Pap A F,
Misselwitz F, Haas S. RECORD2 Investigators .
Extended duration rivaroxaban versus short-term enoxaparin for
the prevention of venous thromboembolism after total hip arthroplasty.
Lancet.
2008;
372
31-39
- 9
Lassen M R, Ageno W, Borris L C, Lieberman J R, Rosencher N, Bandel T J, Misselwitz F,
Turpie A G. RECORD3
Investigators .
Rivaroxaban versus enoxaparin for thromboprophylaxis
after total knee arthroplasty.
New Engl J Med.
2008;
358
2776-2786
- 10
Mueck W, Eriksson B I, Bauer K A, Borris L, Dahl O E, Fisher W D, Gent M, Haas S,
Huisman M V, Kakkar A K, Kalebo P, Kwong L M, Misselwitz F, Turpie A G.
Population
pharmacokinetics and pharmacodynamics of rivaroxaban – an
oral, direct factor Xa inhibitor – in patients undergoing
major orthopaedic surgery.
Clin Pharmacokinetics.
2008;
47
203-16
- 11
Smith P.
Oral anticoagulants are effective long-term after acute myocardial
infarction.
J Intern Med.
1999;
245
383-7
- 12
Stangier J, Rathgen K, Stahle H, Gansser D, Roth W.
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate,
a new oral direct thrombin inhibitor, in healthy male subjects.
Brit J Clin Pharmacol.
2007;
64
292-303
- 13
Wolowacz S E, Roskell N S, Plumb J M, Caprini J A, Eriksson B I.
Efficacy and safety of dabigatran etexilate
for the prevention of venous thromboembolism following total hip
or knee arthroplasty. A meta-analysis.
Thrombos Haemost.
2009;
101
77-85
Prof. Dr. med. H. Darius
Klinik für Innere Medizin, Kardiologie & konservative Intensivmedizin, Vivantes
Klinikum Neukölln
Rudower Str. 48
12351
Berlin
Email: harald.darius@vivantes.de
